- Home
- PRG vs NVCR Comparison
PRG vs NVCR Comparison
Compare PRG & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRG
- NVCR
- Stock Information
- Founded
- PRG 2020
- NVCR 2000
- Country
- PRG United States
- NVCR Switzerland
- Employees
- PRG N/A
- NVCR N/A
- Industry
- PRG Diversified Commercial Services
- NVCR Medical/Dental Instruments
- Sector
- PRG Consumer Discretionary
- NVCR Health Care
- Exchange
- PRG Nasdaq
- NVCR Nasdaq
- Market Cap
- PRG 1.1B
- NVCR 1.9B
- IPO Year
- PRG N/A
- NVCR 2015
- Fundamental
- Price
- PRG $30.18
- NVCR $17.60
- Analyst Decision
- PRG Strong Buy
- NVCR Buy
- Analyst Count
- PRG 5
- NVCR 7
- Target Price
- PRG $41.80
- NVCR $32.43
- AVG Volume (30 Days)
- PRG 375.2K
- NVCR 1.4M
- Earning Date
- PRG 07-23-2025
- NVCR 07-24-2025
- Dividend Yield
- PRG 1.73%
- NVCR N/A
- EPS Growth
- PRG 99.08
- NVCR N/A
- EPS
- PRG 4.90
- NVCR N/A
- Revenue
- PRG $2,505,714,000.00
- NVCR $621,711,000.00
- Revenue This Year
- PRG $1.36
- NVCR $5.56
- Revenue Next Year
- PRG $4.29
- NVCR $9.19
- P/E Ratio
- PRG $6.14
- NVCR N/A
- Revenue Growth
- PRG 4.62
- NVCR 18.27
- 52 Week Low
- PRG $23.50
- NVCR $14.17
- 52 Week High
- PRG $50.28
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- PRG 56.16
- NVCR 49.74
- Support Level
- PRG $29.85
- NVCR $16.81
- Resistance Level
- PRG $30.83
- NVCR $18.59
- Average True Range (ATR)
- PRG 0.79
- NVCR 0.74
- MACD
- PRG 0.06
- NVCR 0.08
- Stochastic Oscillator
- PRG 75.82
- NVCR 56.18
About PRG PROG Holdings Inc.
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.